Jeffrey Liebman

Long-lasting glaucoma fix? They can see it from here

By GREGORY ZELLER // A Stony Brook biotech looking to carve a nanotech niche in the science of glaucoma treatment is eyeing some impressive laboratory results. Sustained Nano Systems, working closely with Stony Brook University’s Center for Biotechnology, has “achieved positive in-vitro results on long-term sustained delivery of Latanaprost for glaucoma treatment,” according to a company statement. Decoded: The biotech can keep the No. 1 glaucoma drug ticking for 159 days in in-vitro tests, which…


An eye on changing (forever) how medicine is taken

By GREGORY ZELLER // As a writer of mystery novels, Barry Libin understands the creative process. (His “The Mystery of the Milton Manuscript,” in fact, may be the vanguard of an entirely new genre: historical-poetry adventure). As a successful entrepreneur, he understands the touch-and-go world of business formation (he sold off a prior startup, Manhasset-based BML Pharmaceuticals, for a “significant” sum back in 2005). And as a trained periodontist, the graduate of Stony Brook University’s…